JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$3.85B |
| 2 |
iShares Core US Aggregate Bond ETF
AGG
|
+$1.5B |
| 3 |
JPMorgan BetaBuilders Canada ETF
BBCA
|
+$1.21B |
| 4 |
Chevron
CVX
|
+$1.08B |
| 5 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$986M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$3.61B |
| 2 |
Occidental Petroleum
OXY
|
+$1.36B |
| 3 |
Merck
MRK
|
+$913M |
| 4 |
Visa
V
|
+$801M |
| 5 |
AT&T
T
|
+$771M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.95% |
| 2 | Technology | 12.9% |
| 3 | Financials | 12.36% |
| 4 | Healthcare | 9.31% |
| 5 | Consumer Discretionary | 8.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3876
PUT
Molson Coors Class B
TAP
$6.89B
| $719K | ﹤0.01% |
+13,000
| New | +$759K |
2019 Q2
0 quarters
|
|
|
NBRV
3877
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $719K | ﹤0.01% |
1,295
+623
| +93% | +$382K |
2018 Q3
3 quarters
|
|
3878
Lindblad Expeditions
LIND
$2.36B
| $716K | ﹤0.01% |
41,013
+7,435
| +22% | +$122K |
2017 Q4
6 quarters
|
|
3879
MGP Ingredients
MGPI
$279M
| $715K | ﹤0.01% |
10,970
+863
| +9% | +$60.8K |
2016 Q3
11 quarters
|
|
|
BFX
3880
DELISTED
BowFlex Inc.
BFX
| $714K | ﹤0.01% |
330,615
+41,316
| +14% | +$163K |
2013 Q2
24 quarters
|
|
3881
Cass Information Systems
CASS
$690M
| $706K | ﹤0.01% |
14,722
+5,615
| +62% | +$263K |
2016 Q4
10 quarters
|
|
3882
CALL
Abercrombie & Fitch
ANF
$6B
| $705K | ﹤0.01% |
+44,500
| New | +$1.03M |
2019 Q2
0 quarters
|
|
|
BPY
3883
DELISTED
Brookfield Property Partners L.P. Limited Partnership Units
BPY
| $705K | ﹤0.01% |
37,234
-145,086
| -80% | -$2.89M |
2015 Q4
14 quarters
|
|
|
WMGI
3884
CALL
DELISTED
Wright Medical Group Inc
WMGI
| $705K | ﹤0.01% |
24,100
-25,900
| -52% | -$790K |
2019 Q1
1 quarter
|
|
|
DOCU
3885
PUT
DocuSign
DOCU
$12.8B
| $704K | ﹤0.01% |
+13,900
| New | +$742K |
2019 Q2
0 quarters
|
|
3886
Sturm, Ruger & Co
RGR
$698M
| $704K | ﹤0.01% |
13,157
-4,221
| -24% | -$224K |
2015 Q2
16 quarters
|
|
|
TEF
3887
DELISTED
Telefonica
TEF
| $704K | ﹤0.01% |
105,455
-47,484
| -31% | -$316K |
2013 Q2
24 quarters
|
|
3888
ESCO Technologies
ESE
$6.95B
| $701K | ﹤0.01% |
8,770
+307
| +4% | +$22.5K |
2016 Q2
12 quarters
|
|
3889
CALL
Philip Morris
PM
$297B
| $701K | ﹤0.01% |
9,000
| – | – |
2014 Q3
19 quarters
|
|
|
3890
PUT
Philip Morris
PM
$297B
| $701K | ﹤0.01% |
9,000
-4,900
| -35% | -$405K |
2018 Q2
4 quarters
|
|
|
BSTC
3891
DELISTED
BioSpecifics Technologies Corp.
BSTC
| $701K | ﹤0.01% |
11,683
+1,220
| +12% | +$76.8K |
2017 Q4
6 quarters
|
|
3892
NACCO Industries
NC
$276M
| $699K | ﹤0.01% |
14,102
-115,129
| -89% | -$5.38M |
2013 Q2
24 quarters
|
|
3893
First Trust Small Cap Core AlphaDEX Fund
FYX
$1.35B
| $698K | ﹤0.01% |
11,515
-87
| -0.7% | -$5.33K |
2013 Q2
24 quarters
|
|
3894
Champion Homes
SKY
$4.66B
| $698K | ﹤0.01% |
25,854
+11,701
| +83% | +$266K |
2016 Q4
10 quarters
|
|
|
AIMT
3895
CALL
DELISTED
Aimmune Therapeutics
AIMT
| $697K | ﹤0.01% |
35,000
-1,100
| -3% | -$22.6K |
2018 Q4
2 quarters
|
|
|
AIMT
3896
PUT
DELISTED
Aimmune Therapeutics
AIMT
| $697K | ﹤0.01% |
35,000
-112,900
| -76% | -$2.32M |
2018 Q4
2 quarters
|
|
3897
CapForce IBD 50 ETF
FFTY
$76.8M
| $695K | ﹤0.01% |
20,421
-24,084
| -54% | -$812K |
2017 Q4
6 quarters
|
|
|
ADAM
3898
Adamas Trust
ADAM
$693M
| $690K | ﹤0.01% |
28,007
+5,571
| +25% | +$138K |
2015 Q3
15 quarters
|
|
|
BNFT
3899
DELISTED
Benefitfocus, Inc.
BNFT
| $690K | ﹤0.01% |
26,358
-51,084
| -66% | -$1.71M |
2017 Q4
6 quarters
|
|
|
OLP
3900
One Liberty Properties
OLP
$485M
| $689K | ﹤0.01% |
23,742
+6,193
| +35% | +$179K |
2017 Q4
6 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2019 Portfolio in Review
As of Q2 2019, JP Morgan Chase held 6,226 positions worth $511B, up 4.5% from $490B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
JP Morgan Chase's Q2 2019 filing shows 458 new, 2,668 increased, 2,116 reduced and 420 closed positions. Its largest new stake was Corteva: 13,119,143 shares worth $388M. The largest sale was iShares 1-3 Year Treasury Bond ETF, an estimated $3.61B.
By sector, the portfolio is most concentrated in Miscellaneous at 28% of assets, up from 27% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q2 2019 buy was Corteva: 13,119,143 shares worth $388M.
- JP Morgan Chase added most to iShares 0-1 Year Treasury Bond ETF in Q2 2019, an estimated $3.85B increase.
- JP Morgan Chase's biggest Q2 2019 reduction was iShares 1-3 Year Treasury Bond ETF, cutting an estimated $3.61B.
- JP Morgan Chase fully exited Goldcorp Inc in Q2 2019, selling an estimated $131M.
- JP Morgan Chase's ten largest holdings make up 16% of its $511B portfolio in Q2 2019.
- JP Morgan Chase opened 458 new positions and closed 420 in Q2 2019.
- JP Morgan Chase's portfolio value rose 4.5% quarter-over-quarter to $511B.
Based on JP Morgan Chase's 13F filing for Q2 2019, filed 7 Aug 2019.